Friday, November 13, 2026
Via News Knowledge File

Dow Jones Industrial Average

organization80% conf.·synced Aug 13, 2026

US stock market index

49
sourced metrics
68
relationships
2
stated objectives
3
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Monthly Return
0percent
Nov 30, 2026⚠ sources conflictsource
Distance From Record Close
3percent
Apr 15, 2026source
Year To Date Return
0.3percent
Apr 10, 2026source
Daily Return
0.58percent
Apr 10, 2026source
Index Level
47909.92points
Apr 8, 2026source
Daily Change
-0.13percent
Apr 3, 2026source
Daily Change Percent
0.48percent
Apr 2, 2026source
Daily Change Points
1000index_points
Mar 31, 2026source
Correction Depth
-10percent
Mar 28, 2026source
Ytd Performance
-6.0percent
Mar 27, 2026source
Weekly Performance
-1.7percent
Mar 27, 2026source
Drawdown From Peak
-10percent
Mar 27, 2026source
Drawdown From High
7.9percent
Mar 27, 2026source
Index Value
-0.81percent
Mar 27, 2026source
Percent Change
-1.0percent
Mar 27, 2026source
Decline Since Iran War
-7percent
Mar 27, 2026source
Closing Price
45960.11points
Mar 26, 2026source
Drawdown From Ath
-7.9percent
Mar 26, 2026source

Stated objectives

Reach 50,000 points

source
target: 50000 stated

Reach 50,000 milestone

source
target: 50000 points stated

Relationship graph · 68 connections

Competes with
16
Covered by
11
located in
11
subsidiary of
8
regulates
5
component of
5
licensed from
2
Member of
2

Via News coverage

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com